JAZZ - Jazz Pharmaceuticals plc
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 121.88 |
| Open | 124.00 |
| Bid | 117.54 x 900 |
| Ask | 126.10 x 800 |
| Day's Range | 120.53 - 125.00 |
| 52 Week Range | 86.88 - 154.24 |
| Volume | 499,551 |
| Avg. Volume | 596,187 |
| Market Cap | 6.676B |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | 24.57 |
| EPS (TTM) | 4.91 |
| Earnings Date | Aug 04, 2020 - Aug 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 153.76 |
- Insider Monkey
Hedge Funds Are Warming Up To Jazz Pharmaceuticals Plc (JAZZ)
In this article we will take a look at whether hedge funds think Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]
- Zacks
Why Is Jazz (JAZZ) Up 4.8% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GuruFocus.com
Top Insider Buys Highlight for the Week of May 29
Insiders loaded up on TJX Companies, Boston Properties, Royal Caribbean Cruises and Jazz Pharmaceuticals Continue reading...
- PR Newswire
Jazz Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences:
- PR Newswire
Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its partners will present seven new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from May 29-June 2, 2020 and six abstracts at the virtual 25th Annual Congress of the European Hematology Association (EHA) from June 11-14, 2020. These new data from Jazz's expanding hematology and oncology portfolio and pipeline are focused on difficult-to-treat cancers, or related disorders, which have few, if any, treatment options.
- Kiplinger
The 11 Best (And 11 Worst) Stocks of the 11-Year Bull Market
It might not feel like it right now, as the coronavirus panic is roiling the stock market. But we're still technically in the longest bull market in history at 132 months and counting - a run that sent the best stocks of the group up by several thousand percent.That might not be the case for much longer, but nothing lasts forever. This bull market is destined to come to an end, like all the rest. But it's still worthwhile to stop and consider a run for stocks that shattered all longevity records.The great 1990s bull market (the previous title holder) lasted 113 months and saw the S&P; 500 advance by 417%. That market occurred during the dot-com era, of course, dominated by new technology stocks. The current bull market - which has seen the S&P; 500 advance by 339% - hasn't been quite as spectacular. But technology has been a big story here as well. Retail, medical devices and fintech also have a healthy representation among the biggest winners.Interestingly, energy stocks, which are under intense pressure right now, were underperformers in both epic bull runs.Today, on the 11th anniversary of the bull market, we're going to take a look at the 11 best stocks over that stretch, as well as the 11 biggest losers. To allow for a bigger pool of stocks, we expanded the universe to the full Russell 1000 Index - the 1,000 largest companies in America's equity market. SEE ALSO: 11 Defensive Dividend Stocks for Riding Out the Storm
- PR Newswire
Bionical Emas and Jazz Pharmaceuticals Enter into an Agreement for Expanded Access to Lurbinectedin in Relapsed Small Cell Lung Cancer in the United States
Bionical Emas and Jazz Pharmaceuticals (NASDAQ: JAZZ) have entered into an agreement to provide appropriate patients in the United States (U.S.) who have relapsed Small Cell Lung Cancer (SCLC) lurbinectedin via an Expanded Access Program (EAP). Lurbinectedin is an investigational drug under review by the U.S. Food and Drug Administration (FDA).
- PR Newswire
Jazz Pharmaceuticals Announces Appointment Of Kim Sablich As Executive Vice President, General Manager Of North America
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Kim Sablich as executive vice president, general manager of North America, effective June 1, 2020. In this role, Ms. Sablich will lead Jazz's newly formed North American regional business structure, including Canada and the U.S., which brings together Medical Affairs, Commercial and Market Access teams for North America to create a strategically-aligned and integrated customer-facing organization. Ms. Sablich will report to Daniel Swisher, president and chief operating officer.
- Motley Fool
Why Jazz Pharmaceuticals' Symphony of Growth Is About to End
Competition is about to ramp up significantly in the $1.7 billion market for treating chronic sleep disorder.
- Thomson Reuters StreetEvents
Edited Transcript of JAZZ earnings conference call or presentation 5-May-20 8:30pm GMT
Q1 2020 Jazz Pharmaceuticals PLC Earnings Call
- Zacks
Jazz Pharma (JAZZ) Misses on Q1 Earnings & Sales, Cuts View
Jazz Pharmaceuticals (JAZZ) reports lower-than-expected first-quarter 2020 earnings and revenues. It lowers its guidance for 2020. Shares drop.
- Motley Fool
Jazz Pharmaceuticals (JAZZ) Q1 2020 Earnings Call Transcript
JAZZ earnings call for the period ending March 31, 2020.
- Motley Fool
Why Jazz Pharmaceuticals Sang Off-Key in Q1
Jazz Pharmaceuticals (NASDAQ: JAZZ) ended 2019 on a positive note, with shares up 20%. Jazz stock is down more than 30%, wiping out all of the 2019 gains and then some. Here's why Jazz sang off-key in Q1.
- Zacks
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of -31.82% and -0.68%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Should You Buy Jazz Pharmaceuticals (JAZZ) Ahead of Earnings?
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Motley Fool
2 Cheap Healthcare Stocks to Buy Now
It's time to shop for healthcare stocks that have suffered so far this year but should rebound in the long term thanks to growth drivers waiting in the wings. The first of these great deals, a pharmaceutical company, has a blockbuster on the market, a newer drug with growing sales, and possible drug approvals in the coming months. Jazz Pharmaceuticals (NASDAQ: JAZZ), a maker of sleep therapeutics and oncology drugs, has steadily grown annual revenue for more than a decade, announcing record annual revenue for 2019.
- PR Newswire
Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic veno-occlusive disease (VOD) post-hematopoietic stem-cell transplantation (HSCT) in high-risk or very high-risk patients is being discontinued. Enrollment in the study was stopped early based on the recommendation from an Independent Data Monitoring Committee (IDMC), which concluded it would be highly unlikely to reach statistical significance for the primary endpoint of VOD-free survival at Day +30 post-HSCT in the final analysis if the study were to complete enrollment.
- Motley Fool
Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy?
Will a small change in a drug's method of delivery be enough to generate over $1 billion in new sales?
- PR Newswire
Jazz Pharmaceuticals to Report 2020 First Quarter Financial Results on May 5, 2020
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 first quarter financial results on Tuesday, May 5, 2020, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss first quarter 2020 financial results and provide a business and financial update.
- Simply Wall St.
Introducing Jazz Pharmaceuticals (NASDAQ:JAZZ), The Stock That Dropped 43% In The Last Five Years
Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both...
- American City Business Journals
The other possible COVID drug: How a biotech giant jumped into the coronavirus fray
The company's rheumatoid arthritis drug blocks an effect of the immune system gone wild — a "storm" that turns COVID-19 deadly.
- American City Business Journals
How 3 Philly-area biopharmaceutical firms are working through coronavirus challenges
Drug developers are considered essential business, but the coronavirus has split staffs between home offices and labs.
- PR Newswire
Jazz Pharmaceuticals Provides COVID-19 Business Update
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today provided an update regarding the impact of COVID-19 on its business and the actions it is taking to mitigate the spread of this virus.
- Investopedia
The Top 10 Biotechnology Companies
The biotechnology industry is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of diseases and medical conditions. Today's biotechnology industry includes companies that make medical devices and diagnostics, as well as biofuels, biomaterials, pollution controls, and more.
- PR Newswire
Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the company's New Drug Application (NDA) seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. JZP-258 is a novel oxybate product candidate with a unique composition of cations resulting in 92%, or approximately 1,000 to 1,500 milligrams, less sodium than Xyrem® (sodium oxybate). Xyrem is the only available product approved to treat both cataplexy and EDS in patients with narcolepsy ages 7 years and older and is the standard of care for treatment of cataplexy. The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is July 21, 2020.
